Ticker

The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing course.

iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Valuation and Earnings This table compares iBio and Gemini

Shares of Gemini Therapeutics, Inc. (NASDAQ: GMTX - Get Free Report) fell 2.6% on Thursday. The company traded as low as $79.0933 and last traded at $80.01. 413,096 shares traded hands during trading, an increase of 118% from the average session volume of 189,291 shares. The stock had previously closed at $82.14. Gemini Therapeutics Stock